Abstract:Background Animal studies suggest vital roles of sphingolipids, especially ceramides, in the pathogenesis of type 2 diabetes (T2D) via pathways involved in insulin resistance, β-cell dysfunction, and inflammation, but human studies are limited. We aimed to evaluate the associations of circulating sphingolipids with incident T2D and to explore underlying mechanisms. Methods and findings The current study included 826 men and 1,148 women who were aged 50–70 years, from Beijing and Shanghai, and without T2D in 2005 and who were resurveyed in 2011. Cardiometabolic traits were measured at baseline and follow-up surveys. A total of 76 sphingolipids were quantified using high-coverage targeted lipidomics. Summary data for 2-sample Mendelian randomization were obtained from genome-wide association studies of circulating sphingolipids and the China Health and Nutrition Survey ( n = 5,731). During the 6-year period, 529 participants developed T2D. Eleven novel and 3 reported sphingolipids, namely ceramides (d18:1/18:1, d18:1/20:0, d18:1/20:1, d18:1/22:1), saturated sphingomyelins (C34:0, C36:0, C38:0, C40:0), unsaturated sphingomyelins (C34:1, C36:1, C42:3), hydroxyl-sphingomyelins (C34:1, C38:3), and a hexosylceramide (d18:1/20:1), were positively associated with incident T2D (relative risks [RRs]: 1.14–1.21; all P < 0.001), after multivariate adjustment including lifestyle characteristics and BMI. Network analysis further identified 5 modules, and 2 modules containing saturated sphingomyelins showed the strongest associations with increased T2D risk (RR Q4 versus Q1 = 1.59 and 1.43; both P trend < 0.001). Mediation analysis suggested that the detrimental associations of 13 sphingolipids with T2D were largely mediated through β-cell dysfunction, as indicated by HOMA-B (mediation proportion: 11.19%–42.42%; all P < 0.001). Moreover, Mendelian randomization evidenced a positive association between a genetically instrumented ceramide (d18:1/20:1) and T2D (odds ratio: 1.15 [95% CI 1.05–1.26]; P = 0.002). Main limitations in the current study included potential undiagnosed cases and lack of an independent population for replication. Conclusions In this study, we observed that a panel of novel sphingolipids with unique structures were positively associated with incident T2D, largely mediated through β-cell dysfunction, in Chinese individuals.

Influence of sphingolipid enzymes on blood glucose levels, development of diabetes, and involvement of pericytes

To Be or Not to Be: The Divergent Action and Metabolism of Sphingosine-1 Phosphate in Pancreatic Beta-Cells in Response to Cytokines and Fatty Acids

Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice

Sphingolipid Metabolism in Type 2 Diabetes and Associated Cardiovascular Complications.

The fate of intracellular S1P regulates lipid droplet turnover and lipotoxicity in pancreatic beta-cells

Sulfation pathways in the maintenance of functional beta-cell mass and implications for diabetes

Role of Sphingosine Kinase in Type 2 Diabetes Mellitus

Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes

251-LB: Association of Plasma Sphingolipids with Insulin Secretion and Insulin Sensitivity in Healthy Black and White Adults

Pancreas-Specific Sirt1-Deficiency in Mice Compromises Beta-Cell Function Without Development of Hyperglycemia.

Deregulation of Mitochondrial Sphingolipid Metabolism in Diabetes

[The biological role of sulfatides]

Heparan sulfate proteoglycans in beta cells provide a critical link between endoplasmic reticulum stress, oxidative stress and type 2 diabetes

Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2

Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis

GT-11 impairs insulin signaling through modulation of sphingolipid metabolism in C2C12 myotubes

The Compensatory Enrichment of Sphingosine -1- Phosphate Harbored on Glycated High-Density Lipoprotein Restores Endothelial Protective Function in Type 2 Diabetes Mellitus

Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: A population-based cohort study in China

Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction

S1P Signaling Pathways in Pathogenesis of Type 2 Diabetes

High-density Lipoprotein of Patients with Type 2 Diabetes Mellitus Upregulates Cyclooxgenase-2 Expression and Prostacyclin I-2 Release in Endothelial Cells: Relationship with HDL-associated Sphingosine-1-phosphate